Gastrointestinal Cancer | Specialty

When You Have Decided to Prescribe Trifluridine/Tipiracil

August 10th 2016

When You Have Decided to Prescribe Regorafenib

August 10th 2016

Treatment Approach in Refractory Colorectal Cancer

August 10th 2016

Colorectal Cancer: Georgetown University's Team Approach

August 10th 2016

Expert Explains Significance of Early Tumor Shrinkage in Metastatic Colorectal Cancer

August 10th 2016

Volker Heinemann, MD, PhD, discusses the connection between early tumor shrinkage and overall survival, depth of response, and what it could mean for the future of metastatic colorectal cancer treatment.

Expert Hopeful About Emerging Options in Pancreatic Cancer Care

August 8th 2016

Eileen O'Reilly, MD, discusses optimal sequencing of therapies for patients with pancreatic cancer, what potential immunotherapy has in the field, and whether the microenvironments and immune privilege within the malignancy should be understood.

A Changing Population and Radiology Advances Mark HCC Field

August 5th 2016

Although it has been nearly 10 years since a new systemic drug has been approved for the treatment of patients with hepatocellular carcinoma, the field is changing rapidly due to new therapies for a prime underlying cause of the disease and advances in interventional radiology.

Dr. Yurgelun on Educating Patients on Genetic Testing for CRC

August 4th 2016

Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.

Dr. El-Jawahri on Early Integrated Palliative Care in Patients With Lung or GI Cancer

July 29th 2016

Areej R. El-Jawahri, MD, assistant in Medicine, Massachusetts General Hospital, instructor in Medicine, Harvard Medical School, discusses a study examining early integrated palliative care for patients with gastrointestinal (GI) or lung cancer and the impact it has on family caregiver outcomes.

Grothey Gives Insight on Nintedanib, Immunotherapy Activity in CRC

July 28th 2016

Axel Grothey, MD, discusses both the LUME-1 and LUME-2 trials, the differences between left and right tumors in colorectal cancer, and how that information could potentially be used in diagnosis and treatment.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer

July 27th 2016

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.

Expert Explores Molecular Biology, Subgroups of Gastric and Esophageal Cancers

July 27th 2016

Adam Bass, MD, discusses the various subclasses of gastric and esophageal cancer, mechanisms by which cancers are activated within a patient from dormancy, and the potential for uncovering an optimal treatment regimen for individual patients.

Dr. Abou-Alfa on Significance of RESORCE Trial for HCC

July 26th 2016

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the significance of the RESORCE trial, which explored regorafenib (Stivarga) versus best supportive care for patients with unresectable hepatocellular carcinoma who progressed after receiving sorafenib (Nexavar).

Dr. Finn on Regorafenib for the Treatment of Patients With HCC

July 25th 2016

Richard Finn, assistant professor of Medicine at the Geffen School of Medicine, Department of Medicine, Division of Hematology/Oncology at UCLA Jonsson Comprehensive Cancer Center, discusses regorafenib (Stivarga) for the treatment of patients with hepatocelluar carcinoma (HCC).

Dr. Van Cutsem on Regorafenib for Patients With Colorectal Cancer

July 25th 2016

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, Leuven, Belgium, discusses regorafenib (Stivarga) as a treatment for patients with colorectal cancer.

CHMP Adopts Positive Opinion for Liposomal Irinotecan in Pancreatic Cancer

July 25th 2016

The Committee for Medicinal Products for Human Use has recommended the approval of pegylated liposomal irinotecan (Onivyde) in combination with fluorouracil and leucovorin for patients with metastatic pancreatic adenocarcinoma following progression on a gemcitabine-based therapy.

Dr. Venook on Evolving Treatment Strategies in CRC

July 22nd 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses how treatment strategies have evolved for patients with colorectal cancer.

Dr. Udit Verma on Managing Regorafenib Side Effects in CRC

July 22nd 2016

Dr. Bekaii-Saab on Dosing Strategies With Regorafenib in CRC

July 22nd 2016

Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses dosing strategies with regorafenib (Stivarga) in patients with colorectal cancer (CRC).

Pancreatic Cancer: Where to Next?

July 20th 2016